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ABSTRACT
Background: Several large epidemiological outcome studies did not demonstrate a benefit
of combined estrogen-progestin replacement treatment (HRT) on cardiovascular events in el-
derly postmenopausal women. Whether progestin antagonism is responsible for these negative
results or the natural estrogen 17ß-estradial (E2) itself is not effective in the coronary circulation
is unknown. Aim: To assess the effect of 3 months of E2 treatment on the coronary circulation,
i.e., on coronary flow reserve (CFR), in postmenopausal women without established coronary
artery disease (CAD). Methods: In a double-blind placebo-controlled cross-over design post-
menopausal women (60 ± 5 years, n = 14) were randomized to either start with placebo or
E2 (Estrofem, Novo Nordisk, Copenhagen, Denmark) 2 mg/d given orally over 3 months and to
switch thereafter for another 3 months of therapy. At baseline, a stress echocardiography was
performed to exclude CAD. CFR was determined by coronary sinus CMR flow measurements
(with motion-adapted gating and interactive acquisition window control; spatial/temporal res-
olution of 0.8 × 0.9 mm2/25–30 ms) which were performed at rest and during vasodilation
(dipyridamole 0.56 mg/kg over 4 minutes IV) at baseline, and after 3 and 6 months of therapy,
respectively. Results: Hemodynamics such as heart rate and systolic and diastolic blood pres-
sure were not different for the control and E2 group. For CFR and for resting and hyperemic
coronary sinus blood flow, no differences between the placebo and E2 group were found (2-way
ANOVA for repeated measurements). Reproducibility of phase-contrast CMR measurements
of CFR was −1.1 ± 4.9%. Conclusions: In elderly postmenopausal women without significant
CAD, oral administration of E2 over 3 months without a progestin co-administration does not
improve CFR. This finding yields partly explanation for some large epidemiological trials which
could not demonstrate a clinical cardiovascular benefit of HRT in elderly women.
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INTRODUCTION
Several observational studies demonstrated that both estrogen
replacement therapy (ERT) and hormone replacement therapy
(HRT) (consisting of estrogen plus progestin) reduce the risk
of coronary artery disease (CAD) (1–4). A variety of beneficial
effects of estrogen on serum lipid levels (5–7), on inflammation
(8, 9), arterial compliance and stiffness (10), and vasomotion
of the brachial artery (11–14) have been reported. Less data are
available for the coronary circulation. The natural 17ß-estradiol
(E2) was shown to induce relaxation of precontracted coronary
artery rings and to inhibit calcium influx in isolated cardiac my-
ocytes (15). In a study of postmenopausal women, ethinyl estra-
diol also acutely attenuated abnormal vasomotor responses of
coronary arteries to acetylcholine (16, 17). Despite this experi-
mental and clinical evidence for favorable effects of estrogens on
vascular pathophysiology, recent randomized controlled trials
showed no benefit in postmenopausal women with CAD (18) or
even an increased risk of cardiovascular events in elderly (mean
age 63–66 years) women both with established CAD (19) or
when predominantly healthy (20), which, however, was not the
case in younger women (4, 21) and not in younger women using
conjugated equine estrogen (CEE) alone (22, 23).
Several mechanisms may explain this discrepancy between
these in part negative epidemiological outcome trials in elderly
women on one hand and the positive smaller clinical studies,
done mostly in younger women, on the other hand. Firstly,
coadministration of a progestin to prevent uterine hyperplasia
and malignancy could abolish the positive effects of estrogens.
Combination of medroxy-progesterone acetate (MPA) with ei-
ther CEE (24) or E2 (25) resulted in a reduced flow-mediated
vasodilation (FMD) of the brachial artery measured by ultra-
sound compared to unopposed estrogen treatment. Also, cycli-
cal E2 combined with norethisterone did not improve FMD (26).
Secondly, some procoagulatory effects of estrogens could offset
beneficial effects on vascular physiology (27). And the last point,
initiation of HRT or ERT in more advanced stages of atheroscle-
rotic disease (28) could prevent hormones from adequate action,
since such action may depend on the integrity of the endothe-
lium and estrogen receptors (29), according to the concept that
estrogens would primarily prevent development of CAD rather
than revert established disease. Besides, CEE or E2 itself may
have limited beneficial long-term effects since many positive ex-
perimental and smaller clinical studies assessed acute effects of
estrogens (16, 17) rather than long-term outcome. Considering
these aspects, the following design was chosen for the current
study. Postmenopausal women were randomized blindly to the
natural estrogen E2 or placebo, and no coadministration of pro-
gestin was allowed. The treatment period was set to 3 months
in order to avoid testing of acute effects, and the study partici-
pants must not have obstructive CAD. The aim of this study was
to test the hypothesis that E2 administered orally over 3 months
without coadministration of progestins would improve coronary
physiology, i.e., coronary flow reserve (CFR) in postmenopausal
women with cardiovascular risk factors (RFs) but without estab-
lished CAD. Due to the restrictive inclusion criteria which would
affect the sample size, a cross-over design was applied. Further-
more, to assess the coronary circulation in a longitudinal study,
noninvasive phase-contrast cardiovascular magnetic resonance
(PC-CMR) flow measurements were performed. The large di-
mension of the coronary sinus (CS) and the fact that it drains a
substantial portion of the left ventricular myocardium are ideal
conditions to measure resting and hyperemic flow in this vessel
by PC-CMR, and hence, to assess CFR (30–32).
MATERIALS AND METHODS
Study population and design
Fourteen postmenopausal women (mean age 60 ± 5 years,
range: 53–67 years) were recruited for this study. They were
eligible if they were between 50–70 years of age, had passed
natural or surgical menopause for at least 1 year, or had folli-
cle stimulating hormone (FSH) levels > 40 IU/L in case they
were hysterectomized. Women with clinically overt CAD and/or
with significant stenoses on x-ray coronary angiography and/or
a positive stress echocardiography examination (within 6 weeks
before study participation) were not eligible as were women
with cardiomyopathies or predominant valvular heart disease.
Also, calcium antagonist treatment was not allowed (since E2
may exert calcium antagonistic effects). Further exclusion cri-
teria were HRT or ERT prior to study participation, a history
and/or evidence of uterine or breast cancer on gynecological
examination (performed within 12 months before study partici-
pation), a history of deep vein thrombosis or thromboembolism,
and contraindications for CMR examination or dipyridamole
administration.
The study protocol was approved by the local Ethics Commit-
tees, and all study participants gave written informed consent.
In a double-blind, placebo-controlled, cross-over design the
study participants were randomized to either start with placebo
or E2 (Estrofem, Novo Nordisk) 2 mg/d given orally over 3
months and to switch thereafter for another 3 months of therapy
(Fig. 1). Randomization was performed by the Institute of Bio-
statistics, University of Zurich, Switzerland (B. Seifert, PhD).
CMR studies were performed at baseline (MR1), and after 3 and
6 months of therapy (MR2 and MR3), respectively.
Figure 1. All women eligible for study participation were randomly
assigned to a treatment/placebo arm in a double-blind fasion and
switch after 3 months to the alternative study arm. Schematic of
the double-blind placebo-controlled cross-over study design. E2:
17ß-estradiol.
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Figure 2. a) Motion Adapted Gating (MAG) controls phase-encoding according to the actual displacement (dx) of the diaphragm. Displacements
within the 5 mm window (a) led to proposals for profile ky = 0. Within a 12 mm window (b) MAG was performed. b) A target function defines the
minimum number of signal averages (NSA [target]) required per profile ky. In case of short-term drifts profiles other than the required can be
averaged until the target function is fulfilled (NSA [current]).
MR imaging
Each subject was imaged in supine position on a 1.5 T sys-
tem (Philips Medical Systems, Best, The Netherlands) using a
5 element cardiac phased-array coil. After measurement of left
ventricular volumes and function by short-axis cine images, lo-
calizers were acquired depicting the CS in-plane. The site of
flow measurements was then defined by an imaging plane tran-
secting the center of both, the left atrium and the aortic root,
thereby cutting the CS perpendicularly (31). To allow for ve-
locity mapping with sufficient spatial and temporal resolutions,
free-breathing acquisitions employing a modified navigator-
based motion-adapted gating (33) and tracking (34) approach
was implemented. A cubic weighting function was used to con-
trol phase-encoding according to the actual displacement of the
diaphragm (Fig. 2a). Small displacements of less than 5 mm
led to the acquisition of central k-space profiles according to
the target function explained below, whereas larger displace-
ments triggered encoding of higher spatial frequencies. Only di-
aphragm displacements within a 17 mm constant gating window
were marked valid. Displacements beyond the 17 mm window
led to rejection of the acquired data. Accepted data could po-
tentially be averaged in the central 45% of k-space according to
the target function shown in Figure 2b, thereby improving the
signal-to-noise ratio in the final images while efficiently using
data in case of high gating efficiencies for the given scan time of
approximately 4 min. For all respiratory positions inside the gat-
ing window of 17 mm, tracking was performed with a correction
factor of 0.8, i.e., a displacement of the diaphragm of 10 mm was
scaled to 8 mm at the level of the coronary sinus cross-section
(35). Since breathing patterns can exhibit temporary changes
and sudden drifts in particular during stress exams in some sub-
jects, the operator was allowed to adapt the gating window level
interactively during the scan, thereby preventing varying gating
efficiencies.
Scan parameters for phase-contrast velocity mapping were as
follows: measured spatial resolution: 0.8 × 0.9 mm2, slice thick-
ness: 5 mm, temporal resolution: 25–30 ms depending on heart
rate, velocity encoding (venc): 60 cm/s/π , TE: 7.8 ms. The two
velocity encoding segments were balanced and measured con-
secutively in the same heart phase. Scan durations were 4:28 min
and 4:05 min on average assuming heart rates of 65 beats/min
and 80 beats/min and gating efficiencies of 85% and 77% during
the resting and stress states, respectively.
Statistics
Values are given as mean ± SD. The assessment of treat-
ment effects on CFR, resting, and hyperemic CS flow as well as
on blood pressure and heart rate involved a repeated measures
ANOVA (2 within factors: treatment groups: E2 vs placebo and
time points: baseline vs follow-up), followed by paired t tests
and Bonferroni’s correction (p < 0.05/4 is significant because
of 4 comparisons; StatView v5.0.1, SAS Institute Inc., USA).
Baseline measurements included all MR1 measurements and
follow-up measurements included the MR2 and MR3 measure-
ments for each treatment group (i.e., MR2 and MR3 for E2 group
vs MR2 and MR3 for the placebo group).
Reproducibility for CFR, resting, and hyperemic CS flow
measurements was calculated from baseline and follow-up stud-
ies under the placebo regimen (all MR1 studies vs MR2 and
MR3 studies of the placebo group). Reproducibility is given as
the mean ± SD of paired measurements (= SDDiff) and corre-
sponding 95% confidence intervals (36).
For an assumed difference in CFR between E2 and placebo
of approximately 10% (37) with an interstudy reproducibility of
4.9% (= SDDiff) by PC-MR, the study yields a power of 90%
to detect differences at a p value of 0.01 in a sample size of 15
subjects (38).
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Table 1. Characteristics of postmenopausal women
n 14
Age (years) 58 ± 5
Height (cm) 161 ± 6
Weight (kg) 67 ± 9
Body mass index (kg/m2) 26 ± 3.7
Estradiol (menopause <100 pmol/L) 48 ± 13
Risk factors: 2.0 ± 0.9
Arterial hypertension 8 (57)
Hypercholesterolemia 4 (29)
Diabetes mellitus 2 (14)
Smoking 1 (7)
Positive family history 1 (7)
Medication:
Beta-blockers 6
ACEI 4
Statins 4
Insulin 2
History of hysterectomy 5
Stress-Echocardiography 11
X-ray coronary angiography 3
Data are mean ± SD or number of patients (%). ACEI =
angiotensin converting enzyme inhibitors.
RESULTS
Demographics of the study population are given in Table 1.
Two patients had to be excluded from the study due to headache
over several days (n = 1) and vomiting after vasodilation at
MR1 (n = 1) resulting in 12 patients included in the analysis.
In the 12 women, 1 CMR study (MR 3) was not evaluable due
to caffeine intake at the day of the CMR study, in 2 patients 1
CMR study was technically inadequate. An example of CMR
images for MR1, MR2, and MR3 is given in Figure 3, together
with corresponding resting and hyperemic CS flow curves in
Figure 4. Medication included antihypertensive treatment (in 8
patients), statins (in 4), and antidiabetic treatment (in 2), which
were all continued during the entire study. Hemodynamics such
as heart rate, systolic, and diastolic blood pressures were not
different for the control and E2 group as shown in Figures 5
and 6, respectively. No differences between the placebo and E2
group were found for hyperemic CS blood flow (p = 0.60; p
value for the interaction between treatment groups and time-
points, repeated measures ANOVA), neither for resting CS blood
flow (p = 0.51; Fig. 7), nor for CFR (p = 0.16; Fig. 8).
Reproducibility for CFR measurements with PC-MR ex-
pressed as mean difference ± SD of paired measurements de-
termined in the placebo group with a mean CFR of 2.55 ± 0.33
was −0.021 ± 0.13 (−1.1 ± 4.9%).
DISCUSSION
The current study results indicate that a 3 month treatment
period of postmenopausal women with E2 does improve nei-
ther maximum myocardial perfusion nor CFR. In the current
study population of postmenopausal women without established
CAD, CFR ranged from 2.35 to 2.96. In a study using PET
imaging similar CFR, values of 2.05 to 2.51 were obtained in
postmenopausal women with RFs (37). In this study by Camp-
isi et al , CFR and dipyridamole-induced hyperemic myocardial
blood flow were 22% and 11% higher during HRT than without
therapy, respectively, although these differences did not reach
statistical significance. However, in their study both, ERT and
HRT were mixed in the active treatment group, which could ex-
plain a lack of CFR improvement due to progestin antagonism.
In the current study with unopposed E2 treatment, no difference
was found between the E2 and the placebo group for both CFR
and dipyridamole-induced hyperemic myocardial blood flow.
These data indicate that CFR and hyperemic myocardial blood
flow do not increase with either E2 alone or with combined es-
trogen/progestin treatment. Assuming that CFR and maximum
myocardial blood flow are reflecting coronary vascular health
status, the current findings are in line with large clinical prospec-
tive trials which demonstrated in elderly postmenopausal and
predominantly healthy women no beneficial effect of HRT (20)
and ERT (23) on cardiovascular event rates.
When comparing the current study results on coronary cir-
culation obtained in women without CAD with those of other
vascular territories such as the brachial or carotid arteries in
Figure 3. Example of magnitude and phase contrast MR images (top and bottom row, respectively) for a subject randomized for placebo during
the first 3 months, followed by 17ß-estradiol treatment during the following 3 months. In the magnitude images (top row), the coronary sinus was
delineated by a region-of-interest (thick line), which was copied to the phase contrast, i.e., flow images (bottom row, thin line).
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Figure 4. Example of resting and stress coronary sinus flow curves derived from the image set shown in Figure 3. P = placebo, E2 = 17ß-estradiol,
Rest 1–3, Stress 1–3, and CFR 1–3 indicate baseline, first follow-up, and second follow-up CMR study, respectively.
postmenopausal women without CAD, similar findings were re-
ported. In a large prospective study testing FMD of the brachial
artery as a marker of vascular health, 253 postmenopausal
women were randomized to either HRT or no therapy and were
followed for a mean of 2.9 years (26). After elimination of 153
patients from analysis due to drop outs, in the 100 remaining
patients, no difference in FMD was found between HRT and
the placebo group. Similarly, in another large study 321 post-
menopausal women were recruited for measurements of carotid
artery distensibility and were randomized to low and high dose
HRT or no therapy. Drop out was 46% and in the remaining popu-
lation, no effect of HRT on distensibility was found (39). Finally,
in a randomized, double-blind, placebo-controlled trial unop-
posed E2 reduced progression of intima-media-thickness mea-
sured by sonography in the carotid arteries in postmenopausal
women compared with placebo but did not influence progression
in those women with controlled lipid levels (40).
In postmenopausal women with established CAD neither
HRT nor ERT had a beneficial effect on the coronary macro-
circulation, i.e., progression of coronary artery stenoses was not
altered (41). However, there were positive effects of E2 on coro-
nary circulatory function in postmenopausal women with es-
tablished CAD by attenuating acetylcholine-induced coronary
artery constriction (17). Similarly, in the forearm microcircu-
lation of postmenopausal women blood flow at baseline (i.e.,
prior to E2 treatment) of 10.2 mL/min/100 g (during acetyl-
choline infusion) increased to 17.9 mL/min/100 g after 12 weeks
of E2 treatment (42). In this study, also sodium nitroprusside-
augmented microcirculatory flow of 10.3 mL/min/100 g further
increased to 17.9 mL/min after 12 weeks of E2 treatment. In
an CMR study in healthy premenopausal women, the forearm
macrocirculation also exhibited increased FMD during mid-
cycle compared with the menstrual phase with high and low
levels of E2, respectively (43).
These findings illustrate that E2 mechanisms of action may
differ in different vascular beds, such as in coronary micro-
circulation (37 and present study), coronary macrocirculation
(17, 41), brachial macrocirculation (26, 43), forearm microcir-
culation (42), and carotid artery macrocirculation (40). Also the
status of the endothelium, i.e., preclinical disease (37, 40 and
the present study) vs established atherosclerotic disease (17, 41)
may influence the effects of E2 treatment on the vascular param-
eters measured. This could be one reason among many others for
the different effects of E2 in different vascular territories since
atherosclerosis is known to progress differently in various vas-
cular regions. It is noteworthy that large randomized clinical tri-
als were negative when performed in women with proven CAD
with respect to clinical outcome (18) as well as morphologic
Figure 5. Bar graph demonstrating heart rates (HR in beat per
minute) during resting and stress condition for the placebo and
17ß-estradiol group. No significant differences occurred. Bpm =
beats per minute.
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Figure 6. Bar graph demonstrating systolic and diastolic blood pressure (BP) during resting and stress condition for the placebo and 17ß-estradiol
group. No significant differences occurred.
progression of CAD (19, 41). In the present study, participants
had preclinical CAD only and, thus, a lack of an E2 effect on
CFR does not directly explain the negative clinical outcome of
the large clinical trials mentioned above. While estrogen recep-
tors are diminished in atherosclerotic lesions in women (29), the
estrogens themselves may show different affinities or different
conformations of the ligand-receptor complex yielding differ-
ent effects in different tissues. The field of selective estrogen
receptor modulators (SERM) opens the opportunity to design
specific compounds which exert beneficial effects in the car-
diovascular system, while being inactive in other tissues, such
as breast or endometrium. Raloxifene, a SERM approved for
osteoporosis prevention and treatment, was shown to restore en-
dothelial nitric oxide release in ovariectomized female rats (44)
and in a subpopulation of women at increased cardiovascular
risk in the MORE trial (Multiple Outcomes of Raloxifene Eval-
uation), fewer cardiovascular events occurred with raloxifene
versus placebo (45). In extended follow up, this advantage was
no longer present, which was discussed in light of selection bias,
Figure 7. Bar graph demonstrating coronary sinus (CS) blood
flow during resting and stress condition for the placebo and 17ß-
estradiol group. No significant differences occurred.
but could also be a consequence of changes in receptor density
with progressive disease (46).
In addition to these pathophysiological considerations
based on prospective, randomized, double-blind, and placebo-
controlled trials (23, 40), some other positive studies (11, 13,
24, 47–51) had some major limitations in study design. Sev-
eral of these positive studies had no placebo control group (13,
24, 48–50), were observational in nature (51), or were small in
sample size (24), which makes correction for underlying RFs
profiles problematic (unless a cross-over design is applied). In
the present study, limitations with regard to study design were
minimized, and as a result, it could be demonstrated that unop-
posed E2 administered orally over 3 months had no beneficial
effect on the myocardial microcirculation in postmenopausal
women without CAD.
Limitations of the study
Although the study was performed in a placebo-controlled,
randomized, double-blind fashion, there still remain some
Figure 8. Mean coronary flow reserve (CFR) for all time points.
17ß-estradiol treatment did not improve CFR in this cross-over
design.
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limitations. Particularly, the treatment period of 3 months might
have been too short for E2 treatment to fully develop the bene-
ficial changes in vascular physiology and/or morphology. How-
ever, if the treatment periods would have been considerably
longer, this could have led to a selection bias toward women
with high acceptance of hormone treatment (subjecting the study
to a limitation similar to observational studies) and maybe a
higher risk of side effects of E2. A second limitation is the age
of the patients; as it has been suggested by a large prospective,
randomized, double-blind and placebo-controlled clinical trial
(21, 23, 52), women with a distance less than 10 years from
menopause may behave differently than women with a more
distant menopause (“window of opportunity”).
Dipyridamole increases myocardial blood flow by acting on
smooth muscle cells. Increased flow then induces endothelium-
mediated vasodilation by increased endothelial shear stress.
Thus, dipyridamole indirectly stimulates endothelial-dependent
flow increase, and accordingly, an impairment of dipyridamole-
induced hyperemic flow has been shown in the presence of RFs
(37). Therefore, it appears justified to use this pharmacological
agent to test whether E2 could revert or mitigate some adverse
effects of RFs on endothelial function.
Finally, neither serum lipids nor inflammatory markers were
measured in this study to focus on the single question: whether
E2 can improve coronary vascular function without addressing
potential mechanisms of E2 action. The treatment regimens be-
tween women were somewhat heterogeneous. The cross-over
design, however, should mostly correct for this limitation (no
treatment was changed during the placebo and treatment phase
in any patient besides the study drug).
Despite the relatively small sample size in this study, the
nonsignificant p value (> 0.05) for differences in CFR indicates
that E2 treatment affects the CFR by less than ±8% (at a power
of 80%), i.e., the effect of E2, if at all present, is unlikely to be
of clinical relevance.
CONCLUSIONS
In elderly postmenopausal women without significant CAD,
oral administration of E2 over 3 months without a progestin
coadministration does not improve CFR. This finding yields
partly explanation for some large epidemiological trials which
could not demonstrate a clinical cardiovascular benefit of HRT
in elderly women.
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